Vascular Depression

09/01/2004 - "The primary purpose of this two-week open study was to examine antidepressant efficacy of rTMS in vascular depression. "
03/01/2010 - "Support for the vascular depression hypothesis in late-life depression: results of a 2-site, prospective, antidepressant treatment trial."
09/01/2004 - "A pharmacological resistance has been described in vascular depression, but, in recent studies, clinical improvement has been observed with antidepressants in more than 80% of cases. "
01/01/2020 - "The underlying mechanisms of the observed relationships may be related to depression, vascular pathology, or direct effects of antidepressants. "
01/01/2019 - "Vascular depression can respond poorly to antidepressants. "

11/01/2020 - "We performed a double-blind randomized study to investigate the efficacy of tDCS as augmentation strategy to sertraline in the treatment of vascular depression, hypothesizing a positive effect in both depressive symptoms and cognitive functions. "

04/01/2015 - "Accumulating evidence suggest that propofol-induced unconsciousness is associated with a global metabolic and vascular depression in the human brain and especially with a significant reduction in the thalamocortical network and the frontoparietal network. "
02/01/2012 - "General anaesthesia with propofol is associated with a global metabolic and vascular depression in the human brain, with significant shifts in regional blood flow and metabolism indicating marked metabolic and vascular responsiveness in some cortical areas and thalamus."
01/01/2013 - "There was significant difference in the number of attempts and ease of LMA insertion between group 2 in comparison with group 3 and group 1. The duration of apnea in group 2 was a (8.67± 6) min, where as it was (18.10±6.25) min in group 1 and (12.03±6.4) min group 3. Etomidate plus propofol is an effective and alternative to propofol and etomidate for facilitating LMA insertion with the added advantage of lack of cardio-vascular depression."
01/01/1989 - "After an initial period of cardio vascular depression, the haemodynamic parameters did not vary much during the anaesthesia and propofol-alfentanil appeared to limit considerably the hypertension due to laryngoscopy. "

08/01/2010 - "There was limited evidence that the lack of improvement with citalopram relative to placebo in CAD patients with a first depression can be attributed to vascular depression."
08/01/2010 - "The present investigation sought to determine whether the differential benefit of citalopram between those with a first depression and those with recurrent depression could be explained by indicators of vascular depression and cardiac disease severity. "
08/01/2009 - "Citalopram for continuation therapy after repetitive transcranial magnetic stimulation in vascular depression."
09/01/2007 - "Besides enhancement of the serotonergic transmission in the brain, the cCBF-increasing effect of citalopram under ischemic conditions may be of benefit in post-stroke and vascular depression."

07/01/2017 - "The present findings suggest that APOE may influence expression of depressive symptomatology as adults age into and beyond their mid-70s but do not indicate APOE as a moderator of vascular depression. "
07/01/2017 - "Results supported the hypothesized path model (root mean square error of approximation = 0.041; comparative fit index = 0.959); however, APOE-conferred risk was not a significant moderator of the 2004 or 2011 vascular depression effect and only approached significance as a predictor of depression in 2011 (P = .079). "
10/01/2007 - "The ApoE epsilon4 allele may be correlated with severe depression in the elderly through ways other than the "vascular depression" hypothesis."
06/15/2007 - "In contrast, the results show no association between the presence of ApoE epsilon4 allele and vascular depression and provide further evidence in support of the concept that ApoE epsilon4 allele is not associated with clinical CVD."
07/01/2017 - "Studies evaluating the effect of apolipoprotein E (APOE) on vascular depression are sparse, employ heterogeneous methods, and yield inconsistent results. "

01/01/2023 - "Augmentation therapy with tandospirone citrate in vascular depression patients with mild cognitive impairment: A prospective randomized clinical trial."
01/01/2019 - "A controlled study of the efficacy and safety of tandospirone citrate combined with escitalopram in the treatment of vascular depression: A pilot randomized controlled trial at a single-center in China."

11/01/2002 - "As ischaemia is known to cause astrogliosis, this study has further tested the "vascular depression hypothesis" by investigating the distribution of the astrocytic marker glial fibrillary acidic protein (GFAP) in the DLPFC and in the anterior cingulate cortex (ACC). "
03/01/2015 - "Effects of kaixin jieyu decoction on behavior and glial fibrillary acidic protein expression in cerebral hippocampus of a rat vascular depression model."

03/01/2002 - "Apolipoprotein E epsilon4 allele and clinically defined vascular depression."
07/01/2017 - "Studies evaluating the effect of apolipoprotein E (APOE) on vascular depression are sparse, employ heterogeneous methods, and yield inconsistent results. "

01/01/2019 - "This study aimed to explore the efficacy and safety of tandospirone plus escitalopram for treating vascular depression with anxiety. "
01/01/2023 - "Augmentation therapy with tandospirone citrate in vascular depression patients with mild cognitive impairment: A prospective randomized clinical trial."
01/01/2019 - "A controlled study of the efficacy and safety of tandospirone citrate combined with escitalopram in the treatment of vascular depression: A pilot randomized controlled trial at a single-center in China."
01/01/2019 - "Augmentation of escitalopram with tandospirone accelerates the onset of anti-depressive and anxiolytic effects and improves cognitive function in patients with vascular depression and anxiety."

03/01/2018 - "The objective of the study was to identify biomarkers related to vascular depression in hippocampus and explore the antidepressive effects of YXST on the mouse model. "

11/01/2020 - "Transcranial direct current stimulation: A novel approach in the treatment of vascular depression."
11/01/2020 - "We performed a double-blind randomized study to investigate the efficacy of tDCS as augmentation strategy to sertraline in the treatment of vascular depression, hypothesizing a positive effect in both depressive symptoms and cognitive functions. "
11/01/2020 - "tDCS as augmentation treatment of an adequate pharmacotherapy is a potential strategy in the management of vascular depression, a disease known to be often unresponsive to antidepressants only. "

11/09/2013 - "Different patterns of cortical excitability in major depression and vascular depression: a transcranial magnetic stimulation study."
01/01/2010 - "Subgenual cingulate theta activity predicts treatment response of repetitive transcranial magnetic stimulation in participants with vascular depression."
08/01/2009 - "The authors previously reported that repetitive transcranial magnetic stimulation (rTMS) produced a response rate of 39.4% among 62 patients with treatment resistant vascular depression. "
03/01/2008 - "Treatment of vascular depression using repetitive transcranial magnetic stimulation."
12/01/2016 - "This study aims to perform a systematic review evaluating the effectiveness of repetitive transcranial magnetic stimulation (rTMS) in improving depression resulting from cerebrovascular disease including vascular depression (VD) and poststroke depression (PSD). "

04/01/2012 - "Although depression care use was significantly higher among vascular depression respondents relative to those with major depression alone, practice guideline concordant therapy use was not. "
01/01/2012 - "However, the prognosis of patients with vascular depression is different and these patients respond less well to the usual therapy. "
12/28/2021 - "Vascular burden is associated with cognitive deficits and a specific form of LLD, vascular depression, which is marked by decreased white matter integrity, executive dysfunction, functional disability, and poorer response to antidepressive therapy than major depressive disorder without vascular risk factors. "
12/15/2006 - "Subcortical ischemic depression affects clinical presentation, long-term outcomes, and response to antidepressant therapy, arguing that it is a valid diagnostic entity worth further study."
08/01/2009 - "Citalopram for continuation therapy after repetitive transcranial magnetic stimulation in vascular depression."

01/01/2018 - "Pharmacotherapies used in the prevention and treatment of cerebrovascular disease may help prevent vascular depression. "
11/01/2020 - "tDCS as augmentation treatment of an adequate pharmacotherapy is a potential strategy in the management of vascular depression, a disease known to be often unresponsive to antidepressants only. "

04/01/2017 - "Control variables included gender, age, marital status, schooling, hypertension, diabetes, dyslipidaemia, hypothyroidism, depression, vascular diseases, polymedication, use of benzodiazepines, exposure to tobacco, sedentary lifestyle, obesity and functional capacity. "